Finn Myhren

571 citations
17 papers · 438 indexed · h-index 12
Topics
HIV/AIDS drug development and treatment (6 papers)Cytomegalovirus and herpesvirus research (4 papers)Chronic Lymphocytic Leukemia Research (3 papers)
Partner nations
NetherlandsNorwayBelgium

In The Last Decade

Finn Myhren

17 papers receiving 419 citations

Peers

Finn Myhren
Comparison fields: 5 of 65
  • Molecular Biology 275
  • Oncology 124
  • Infectious Diseases 79
  • Biomaterials 64
  • Organic Chemistry 63
Replace Marit Liland Sandvold with:
Marit Liland Sandvold Netherlands
Paul L. Chello United States
D Boesch Switzerland
B Jachez France
E. Tripp Australia
Chang‐Soo Yun South Korea
Aiping Young Canada
G Razaka France
Satoshi Yotsumoto Japan
Κ.S. Vitols United States
Finn Myhren relative to Marit Liland Sandvold Netherlands Marit Liland Sandvold's profile →
Citations per field
00.5×1.5×
Marit Liland Sandvold · 1×
Citations per year

Countries citing papers authored by Finn Myhren

Since Specialization
Citations

This map shows the geographic impact of Finn Myhren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Finn Myhren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Finn Myhren more than expected).

Fields of papers citing papers by Finn Myhren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Finn Myhren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Finn Myhren. The network helps show where Finn Myhren may publish in the future.

Co-authorship network of co-authors of Finn Myhren

This figure shows the co-authorship network connecting the top 25 collaborators of Finn Myhren. A scholar is included among the top collaborators of Finn Myhren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Finn Myhren. Finn Myhren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
#WorkIndexed citations
1 42
2 78
3 15
4 12
5 26
6
Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab, and trastuzumab in human NSCLC xenografts
2
7 22
8 25
9 73
10 14
11 8
12 4
13
Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
63
14 23
15 20
16 8
17 3

About Finn Myhren

Finn Myhren is a scholar working on Infectious Diseases, Oncology and Toxicology, having authored 17 papers that have together received 438 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (6 papers), Cytomegalovirus and herpesvirus research (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Physiology (35 citations), Hematology (55 citations) and Biomaterials (64 citations). Finn Myhren has collaborated with scholars based in Netherlands, Norway and Belgium. Frequent co-authors include Marit Liland Sandvold, Godefridus J. Peters, Hans R. Hendriks, Andries M. Bergman, Øystein Fodstad, Jan Balzarini, Erik De Clercq, C.M. Kuiper, Daphne Voorn and Knut Breistøl. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Biochemical Pharmacology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026